HRTS
Tema Obesity & Cardiometabolic ETF · NAS
- Category Equity
- Expense Ratio 0.75%
- Listing Date Nov 21, 2023
- Volume 19,618.0
- Market Cap (AUM) $60.71M
Performance
+0.85%
1W
-3.14%
1M
-1.53%
3M
+20.64%
6M
+4.93%
YTD
+20.64%
1Y
Top Holdings
-
Name
Symbol%Assets
- Vertex Pharmaceuticals IncorporatedVRTX5.41%
- Eli Lilly and CompanyLLY5.08%
- Amgen Inc.AMGN5.05%
- Novo Nordisk A/S Class BNOVO.B4.86%
- DexCom, Inc.DXCM4.21%
- Insulet CorporationPODD2.90%
- Medtronic PlcMDT2.86%
- Cytokinetics, IncorporatedCYTK2.84%
- Edwards Lifesciences CorporationEW2.82%
- Alnylam Pharmaceuticals, IncALNY2.78%
Technical Analysis of HRTS 2024-05-10
Overview:
In analyzing the technical indicators for HRTS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.
Trend Indi...
Recent News & Updates
- 2024-04-21 23:10
10 Best Performing Biotech ETFs in 2024(Insidermonkey)
- 2024-03-13 12:40
'Continued innovation' is key when investing in weight loss trend(Yahoo Finance Video)
Page 1 of 1
previousnext